IN THE CLAIMS

Please **delete** the sequence listing of record and **substitute** therefor the Third Substitute Sequence Listing enclosed herewith in paper and computer-readable form.

IN THE CLAIMS

Please **amend** claims 10-12 and 15-16 as follows:

10. [TWICE AMENDED] The process according to claim 9, wherein the ligand comprises ~~Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH_2,~~ the amino acid sequence of SEQ ID NO:4 that is phosphorylated at amino acids 5 and 7, and particular is SEQ ID NO:4 that is phosphorylated at amino acids 5 and 7 and has 5-TAMRA-AEEA-~~Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH_2.~~ at the carboxy terminus.

11. [AMENDED] The process according to ~~caim~~claim 1, wherein the assay is performed as a fluorescence immunoassay, in particular a fluorescence polarization immunoassay, a fluorescence correlation spectroscopic assay, a fluorescence resonance energy transfer assay, or a fluorescence intensity distribution assay.

12. [AMENDED] The process according to ~~caim~~claim 1, wherein X in the sequence motif comprises proline or glutamate or glycine.

15. [AMENDED] The process according to claim 1, wherein the peptide comprises the amino acid sequence ~~H-Lys-Phe-Met-Met-Thr-Pro-pTyr-Val-Val-Thr-Arg-NH_2 (p means~~of SEQ ID NO:2 wherein amino acid 5 is phosphorylated~~)~~.

16. [AMENDED] The process according to claim 1, wherein the peptide ~~is composed of~~comprises the amino acid sequence ~~H-Lys-Phe-Met-Met-Thr-Pro-pTyr-Val-Val-Thr-Arg-NH_2 (p means~~of SEQ ID NO:1 wherein amino acid 7 is phosphorylated~~)~~.